ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 625

Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Systemic Disease

Frederick B Vivino1, Steven E. Carsons2, Ann Parke3, Nancy Carteron4, Vidya Sankar5, Richard Brasington6, Robert Fox7, William Ehlers3, Michael Brennan8, Robert Hal Scofield9, Katherine M Hammitt10 and Sjogren's Syndrome Foundation Clinical Practice Guidelines Committee, 1Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Rheumatology, Allergy and Immunology, Winthrop University Hospital, Mineola, NY, 3University of Connecticut, Farmington, CT, 4University of California, San Francisco, CA, 5Univeristy of Texas, San Antonio, TX, 6Washington University, St Louis, MO, 7Rheumatology Clinic, La Jolla, CA, 8Carolinas Medical Center, Charlotte, NC, 9Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 10Vice President of Medical and Scientific Affairs, Sjögren's Syndrome Foundation, Bethesda, MD

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: clinical practice guidelines and treatment, Sjogren's syndrome, Systemic Inflammatory

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Sjögren's Syndrome Poster I: Clinical Insights into Sjögren's Syndrome

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: There are currently no FDA approved immunomodulating agents available for treatment of the extraglandular manifestations of Sjogren’s (SS).  Clinical practice guidelines were developed for the rheumatologic/systemic manifestations of SS in order to improve quality and consistency of care.

Methods: Following the principles of AGREE and ACR recommendations for guidelines development, key stakeholders were surveyed to define clinically important management issues. Of 97 initial questions, 16 were selected for rheumatology guidelines development, redefined using the PICO (Patient, Intervention, Comparison, Outcome) format and prioritized. Guidelines development was completed for the first 3 topics: use of DMARDS for treatment of inflammatory musculoskeletal pain (MSK), management of fatigue and use of biological therapy. Each PICO question was assigned to a 3 member topic review group (TRG) for systematic literature review, data extraction and drafting of one or more guidelines. All articles were reviewed by at least 2 TRG members. Quality of evidence and strength of recommendation were rated using a modification of GRADE. Guidelines were drafted based on the available medical evidence and/or expert opinion. The clinical rationale, evidence summaries, data extraction tables, and drafted recommendations were submitted to a consensus expert panel for consideration and approval. Each panel was comprised of 30-40 participants including clinicians (rheumatologists, other specialists), nurses and patients.  A modified Delphi process was used with 75% agreement required for consensus. Revision of guidelines that failed to achieve consensus was permitted up to 3 rounds before the recommendation was discarded.

Results: Consensus was achieved for 20 guideline recommendations.  Eighteen recommendations required 1 Delphi round, 1 required 2 and 1 required 3.  Key recommendations included: 1) a decision tree for the use of oral DMARDs for MSK with hydroxychloroquine (HCQ) as first line therapy; 2) use of self-care measures and exercise to reduce fatigue and the use of HCQ in selected patients with fatigue. The committee also recommended that 3) the use of rituximab may be considered in certain clinical situations including, vasculitis with or without cryoglobulinemia, severe parotid swelling, inflammatory arthritis, pulmonary disease and mononeuritis multiplex;  The committee 4) strongly discouraged the use of TNFα inhibitors for sicca symptoms and for the majority of clinical contexts in primary SS.

Conclusion: Development of clinical practice guidelines for systemic manifestations should improve the standard and uniformity of care for SS and help define areas for future study. The guidelines committee updates its systematic reviews regularly and will revise recommendations as needed.  

The Sjögren’s Syndrome Foundation (SSF) Clinical Practice Guidelines are fully supported by the SSF with no pharmaceutical support.  No compensation was paid to any author. All participating authors completed Conflict of Interest forms of the American College of Rheumatology.


Disclosure: F. B. Vivino, Biogen Idec, 5,Takeda International, Inc, 5,Immco Diagnostics, Inc, 5,NiCox, Inc, 5; S. E. Carsons, None; A. Parke, UCB, 8,GlaxoSmithKline, 5,UptoDate, 7,Biogen Labs, 5,NIH, 2; N. Carteron, Penguin, 7,Genetech Roche, 1,Regeneron, 1,CVS Health Corp, 1; V. Sankar, Clinical Assistance Program, 5; R. Brasington, Amgen, 1,Pfizer Inc, 8,GlaxoSmithKline, 2; R. Fox, UCB, 5,Web MD, 5,Takeda, 5,Pfizer Inc, 5,Allergan, 5; W. Ehlers, None; M. Brennan, NIH/NIDCR, 2; R. H. Scofield, Lilly, UCB, 5; K. M. Hammitt, None.

To cite this abstract in AMA style:

Vivino FB, Carsons SE, Parke A, Carteron N, Sankar V, Brasington R, Fox R, Ehlers W, Brennan M, Scofield RH, Hammitt KM. Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Systemic Disease [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/sjogrens-syndrome-foundation-clinical-practice-guidelines-for-management-of-systemic-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sjogrens-syndrome-foundation-clinical-practice-guidelines-for-management-of-systemic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology